Our differentiated therapies have the potential to set new standards for efficacy and patient response rates across various difficult-to-treat cancers. The Company, established in 2017 is based on seminal research conducted at the Hebrew University of Jerusalem and the University of Rijeka. Our technology addresses major escape mechanisms of current IO therapies through a diverse pipeline of novel monoclonal antibodies (mAbs) and antibody-drug-conjugates (ADCs). In late 2022 we launched phase 1 of a clinical trial for NTX1088, our first-in-class anti-PVR targeted immunotherapy for the treatment of patients with advanced solid tumors together with MD Anderson and entered into a clinical trial collaboration agreement with MSD (Merck).
Nectin Therapeutics has an established scientific and management team with deep experience in oncology R&D, a successful track record in building biotech companies and developing innovative therapies. Nectin Therapeutics is a venture-backed, privately held company, funded by aMoon Fund, Peregrine Ventures, IBF, Integra Holdings, Cancer Focus Fund, and Myeloma Investment Fund.
